UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study

The pharmacogenomics journal, 2016-02, Vol.16 (1), p.54-59

2016

Volltextzugriff (PDF)

A phase I study of sirolimus and bevacizumab in patients with advanced malignancies

European journal of cancer (1990), 2011-07, Vol.47 (10), p.1484-1489

2011

Volltextzugriff (PDF)

Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling

Clinical pharmacology and therapeutics, 2013-04, Vol.93 (4), p.345-351

2013

Volltextzugriff (PDF)

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

Clinical pharmacology and therapeutics, 1999-05, Vol.65 (5), p.576-582

1999

Volltextzugriff (PDF)

Potential for value-based prescribing of oral oncology drugs

Annals of oncology, 2018-10, Vol.29, p.viii562-viii562

2018

Volltextzugriff (PDF)

Perceptions of cancer patients and their physicians involved in phase I trials

Journal of clinical oncology, 1995-05, Vol.13 (5), p.1062-1072

1995

Volltextzugriff (PDF)

A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors

Annals of oncology, 2005-06, Vol.16 (6), p.958-965

2005

Volltextzugriff (PDF)

Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?

Journal of clinical oncology, 1998-07, Vol.16 (7), p.2297-2298

Ratain, M J

1998

Volltextzugriff (PDF)

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

The Journal of clinical investigation, 1998-02, Vol.101 (4), p.847-854

1998

Volltextzugriff (PDF)

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863

Annals of oncology, 2003-12, Vol.14 (12), p.1783-1790

2003

Volltextzugriff (PDF)

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy

Annals of oncology, 2023-08, Vol.34 (8), p.638-644

2023

Volltextzugriff (PDF)

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia

The pharmacogenomics journal, 2018-01, Vol.18 (1), p.35-42

2018

Volltextzugriff (PDF)

A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine

Annals of oncology, 2004-11, Vol.15 (11), p.1705-1711

2004

Volltextzugriff (PDF)

Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor

Clinical and experimental dermatology, 2006-11, Vol.31 (6), p.783-785

2006

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients

Journal of clinical oncology, 1997-04, Vol.15 (4), p.1502-1510

1997

Volltextzugriff (PDF)

Meaningful Use of Pharmacogenetics

Clinical pharmacology and therapeutics, 2014-12, Vol.96 (6), p.650-652

2014

Volltextzugriff (PDF)

Biomarkers in Early Cancer Drug Development: Limited Utility

Clinical pharmacology and therapeutics, 2009-02, Vol.85 (2), p.134-135

2009

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565

Journal of clinical oncology, 2000-07, Vol.18 (14), p.2780-2787

2000

Volltextzugriff (PDF)

Pharmacogenetics and cancer chemotherapy

European journal of cancer (1990), 1998-09, Vol.34 (10), p.1493-1499

1998

Volltextzugriff (PDF)

Metabolic fate of irinotecan in humans : correlation of glucuronidation with diarrhea

Cancer research (Chicago, Ill.), 1994-07, Vol.54 (14), p.3723-3725

1994

Volltextzugriff (PDF)

Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling

Clinical and translational science, 2016-02, Vol.9 (1), p.43-50

2016

Volltextzugriff (PDF)

Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan

Drug metabolism and disposition, 2001-04, Vol.29 (4 Pt 2), p.596

2001

Volltextzugriff (PDF)

Challenges in Interpreting the Evidence for Genetic Predictors of Ototoxicity

Clinical pharmacology and therapeutics, 2013-12, Vol.94 (6), p.631-635

2013

Volltextzugriff (PDF)

Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7

Drug metabolism and disposition, 2001-05, Vol.29 (5), p.686

2001

Volltextzugriff (PDF)

Are Drug Labels Static or Dynamic?

Clinical pharmacology and therapeutics, 2013-09, Vol.94 (3), p.302-304

2013

Volltextzugriff (PDF)

26 – 50 von 552

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(532)
Mit Volltextzugriff
(490)

Publikationsform

Sprache

Englisch
(552)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(354)
Science & Technology
(350)
Life Sciences & Biomedicine
(347)
Oncology
(252)
Biological And Medical Sciences
(219)
Medical Sciences
(217)
Female
(185)
Pharmacology. Drug Treatments
(184)
Male
(182)
Middle Aged
(167)
Aged
(154)
Adult
(144)
Antineoplastic Agents
(143)
Neoplasms - Drug Therapy
(115)
Pharmacology & Pharmacy
(102)
Chemotherapy
(94)
Aged, 80 And Over
(62)
Antineoplastic Agents - Adverse Effects
(48)
Antineoplastic Agents - Therapeutic Use
(46)
Dose-Response Relationship, Drug
(46)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study

A phase I study of sirolimus and bevacizumab in patients with advanced malignancies

Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

Potential for value-based prescribing of oral oncology drugs

Perceptions of cancer patients and their physicians involved in phase I trials

A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors

Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia

A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine

Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients

Meaningful Use of Pharmacogenetics

Biomarkers in Early Cancer Drug Development: Limited Utility

Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565

Pharmacogenetics and cancer chemotherapy

Metabolic fate of irinotecan in humans : correlation of glucuronidation with diarrhea

Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling

Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan

Challenges in Interpreting the Evidence for Genetic Predictors of Ototoxicity

Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7

Are Drug Labels Static or Dynamic?

Suchergebnisse filtern